Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya.
Adolescent girls and young women
DREAMS Initiative
HIV prevention
PrEP, survival analysis
persistence
Journal
AIDS care
ISSN: 1360-0451
Titre abrégé: AIDS Care
Pays: England
ID NLM: 8915313
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
pubmed:
22
9
2020
medline:
25
5
2021
entrez:
21
9
2020
Statut:
ppublish
Résumé
The Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe (DREAMS) Initiative aims to reduce HIV infections among adolescent girls and young women (AGYW) in Africa. Oral pre-exposure prophylaxis (PrEP) is offered through DREAMS in Kenya to eligible AGYW in high burden counties including Kisumu and Homa Bay. This study examines PrEP persistence among AGYW in high burden community-based PrEP delivery settings. We evaluated PrEP persistence among AGYW in the DREAMS PrEP program in Kisumu and Homa Bay using survival analysis and programmatic PrEP refill data collected between March through December 2017. Among 1,259 AGYW who initiated PrEP during the study period, the median persistence time in the program was 56 days (95% CI: 49-58 days) and the proportion who persisted 3 months later was 37% (95% CI: 34-40%). Persistence varied by county (
Identifiants
pubmed: 32951437
doi: 10.1080/09540121.2020.1822505
pmc: PMC7981281
mid: NIHMS1628162
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
712-720Subventions
Organisme : NICHD NIH HHS
ID : R01 HD094682
Pays : United States
Références
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Osteoporos Int. 2015 Jun;26(6):1831-40
pubmed: 25822104
Sci Transl Med. 2011 Dec 7;3(112):112re4
pubmed: 22158861
J Int AIDS Soc. 2019 Jan;22(1):e25225
pubmed: 30657642
J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25298
pubmed: 31328444
Curr HIV/AIDS Rep. 2019 Apr;16(2):141-150
pubmed: 30796608
AIDS. 2017 Mar 13;31(5):731-734
pubmed: 28060019
BMC Public Health. 2018 Jan 31;18(1):203
pubmed: 29386001
J Virus Erad. 2016 Jul 01;2(3):149-55
pubmed: 27482454
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50
pubmed: 23600365
J Int AIDS Soc. 2020 Jun;23 Suppl 3:e25537
pubmed: 32602658
AIDS. 2001 Aug;15 Suppl 4:S51-60
pubmed: 11686466
PLoS Med. 2019 Sep 3;16(9):e1002885
pubmed: 31479452
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19408
pubmed: 25724504
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
BMC Public Health. 2016 Nov 3;16(1):1136
pubmed: 27809824
PLoS One. 2018 Dec 13;13(12):e0208243
pubmed: 30543640
Lancet HIV. 2016 Sep;3(9):e406-e408
pubmed: 27562739
PLoS One. 2007 Oct 03;2(10):e1001
pubmed: 17912340
Lancet Infect Dis. 2013 Jan;13(1):65-76
pubmed: 23257232
Curr Opin HIV AIDS. 2018 May;13(3):265-273
pubmed: 29528850
Curr HIV/AIDS Rep. 2011 Mar;8(1):62-72
pubmed: 20941553
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):53-63
pubmed: 28991885
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20227
pubmed: 26198350
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608
pubmed: 27846073
Open AIDS J. 2016 Apr 08;10:34-48
pubmed: 27347270
PLoS One. 2018 Dec 7;13(12):e0208167
pubmed: 30532210
J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S144-53
pubmed: 24918590
Lancet. 2010 Jul 3;376(9734):41-8
pubmed: 20557928
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Clin Infect Dis. 2021 Feb 1;72(3):379-385
pubmed: 33527117
Open AIDS J. 2018 Jul 19;12:53-67
pubmed: 30123385
Sex Health. 2018 Nov;15(6):578-586
pubmed: 30408432
AIDS. 2004 Jul 2;18(10):1435-42
pubmed: 15199320